AMBER Ursodeoxycholic acid
|
tablets 150mg, capsules 250mg
|
suspension 250mg in 5mL
|
RED Obeticholic acid▼ NHS England Commissioned
|
film coated tablets 5mg, 10mg
|
Patients should be reviewed 12 months after initiation to review effectiveness and treatment should only
|
| continue if there is evidence of clinical benefit - as per NICE TA443 |
| |
| Pruritis secondary to primary sclerosing cholangitis |
| 1st line option, unlicensed indication. |
| CAUTION: should not be prescribed alongside another statin |
| AMBER Bezafibrate tablets 200mg, 400mg |
| |
| |
| Palliative Use Only: Bowel Obstruction - GI secretions associated with bowel obstruction. |
| (suitable for initiation in Primary Care in line with restrictions) |
GREEN (Restricted) Octreotide 500micrograms/ml solution for injection
|
| See Quick Guide: Bowel Obstruction |
| [For full guidance see LSC Palliative Care Clinical Practice Summary] |
| |
1.9.2 Bile acid sequestrants |
GREEN Colestyramine sachets 4g (Questran Light®)
|
| |
1.9.4 Pancreatin |
GREEN Creon® 10,000 capsules (protease 600/lipase 10,000/amylase 8000)
|
GREEN Creon® 25,000 capsules (protease 1,000/lipase 25,000/amylase 18,000)
|
| AMBER Creon® micro granules (Amylase 3600 unit, Lipase 5000 unit, Protease 200 unit) |
| [Paediatric use ONLY/specialist initiation] |
AMBER Nutrizym 22® capsules (Amylase 19800 unit/Lipase 22000 unit/Protease 1100 unit) - second line option when
|
| creon® not tolerated |
RED Pancrex V Powder® administration via enteral feeding tubes to reduce malabsorption in patients on enteral feeds.
|
| Gastroenterology use ONLY |
| |
| BACK to main chapter |
